Disease-modifying therapies in relapsing–remitting multiple sclerosis

  • González-Andrade J
  • Jose Alcaraz
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Clinical question: What is the best current disease-modifying therapy for relapsingremitting multiple sclerosis? Results: The evidence shows that the most effective disease-modifying therapy for delaying short- to medium-term disability progression, prevention of relapses, reducing the area and activity of lesions on magnetic resonance imaging, with the least side effects, is high-dose, high-frequency subcutaneous interferon- 1a 44 g three times per week. Implementation: The pitfalls in treatment of MS can be avoided by remembering the following points: The most effective therapy to prevent or delay the appearance of permanent neurological disability with the fewest side effects should be chosen, and treatment should not be delayed. Adherence to treatment should be monitored closely, and needs comprehensive patient information and education to establish long-term adherence, which is a critical determinant of long-term outcome. The correct approach to the disease includes disease management, symptom management, and patient management. A combination of tools is necessary to ease the various symptoms, which fall into three broad categories, i.e. rehabilitation, pharmacological, and procedural. It is important to understand that no treatment modality should be used alone, unless it is in itself sufficient to remedy the particular symptom/problem.

Cite

CITATION STYLE

APA

González-Andrade, J. F., & Jose Alcaraz. (2010). Disease-modifying therapies in relapsing–remitting multiple sclerosis. Neuropsychiatric Disease and Treatment, 365. https://doi.org/10.2147/ndt.s11079

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free